FDA: Irbesartan Under Recall Too in the Midst of Valsartan Saga
Another ARB found to contain a potential carcinogen in some lots
ScieGen's angiotensin II receptor blocker (ARB) irbesartan is under recall due to a carcinogenic impurity found during lab testing, the FDA warned in a MedWatch Safety Alert.